Abstract
Background. Urinary tract infections (UTIs) are common and important clinical problem in childhood, and extended-spectrum-beta-lactamase- (ESBL-) producing organisms are the leading cause of healthcare-related UTIs. In this study, we aimed to evaluate the clinical efficacy and safety of ertapenem therapy in children with complicated UTIs caused by ESBL-producing organisms. Methods. Seventy-seven children with complicated UTIs caused by ESBL-producing organisms were included in this retrospective study, and all had been treated with ertapenem between January 2013 and June 2014. Results. Sixty-one (79%) females and sixteen (21%) males with a mean ± standard deviation (SD) age of 76.6 ± 52 months (range 3–204, median 72 months) were enrolled in this study. Escherichia coli (E. coli) (n = 67; 87%) was the most common bacterial cause of the UTIs followed by Klebsiella pneumoniae (K. pneumoniae) (n = 9; 11.7%) and Enterobacter cloacae (E. cloacae) (n = 1; 1.3%). The mean duration of the ertapenem therapy was 8.9 ± 1.6 days (range 4–11). No serious drug-related clinical or laboratory adverse effects were observed, and the ertapenem therapy was found to be safe and well tolerated in the children in our study. Conclusion. Ertapenem is a newer carbapenem with the advantage of once-daily dosing and is highly effective for treating UTIs caused by ESBL-producing microorganisms.
Highlights
Urinary tract infections (UTIs) are common bacterial infections in infants and children and have high prevalence and morbidity rates
Fourteen (18.2%) had a neurological abnormality, 10 (13%) had vesicoureteral reflux (VUR), 10 (13%) had an anatomic anomaly, six (7.8%) had bladder dysfunction representing with enuresis, four (5.2%) had undergone chronic hemodialysis, three (3.8%) had urolithiasis, and four (5.2%) had other anomalies, including two with cerebral palsy (CP), one with a malignancy, and one with congenital myasthenia gravis (Table 1)
Ertapenem was initiated in all of the patients after the results of the microbiological cultures became available, and we determined that Escherichia coli (E. coli) (n = 67; 87%) was the most common bacterial cause of the UTIs
Summary
Urinary tract infections (UTIs) are common bacterial infections in infants and children and have high prevalence and morbidity rates. Cephalosporins are mostly not effective for UTIs caused by ESBL-producing microorganisms, with the management of these infections being complicated by the increasing prevalence of these microorganisms in both healthcare-related and communityacquired UTIs. In our country, the data showed that prevalence of ESBL-producing bacteria in children is increasing, ranging from 20% to 54% [2, 3]. Urinary tract infections (UTIs) are common and important clinical problem in childhood, and extended-spectrumbeta-lactamase- (ESBL-) producing organisms are the leading cause of healthcare-related UTIs. In this study, we aimed to evaluate the clinical efficacy and safety of ertapenem therapy in children with complicated UTIs caused by ESBL-producing organisms. Seventy-seven children with complicated UTIs caused by ESBL-producing organisms were included in this retrospective study, and all had been treated with ertapenem between January 2013 and June 2014. Ertapenem is a newer carbapenem with the advantage of once-daily dosing and is highly effective for treating UTIs caused by ESBL-producing microorganisms
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
